---
title: "Decoy Therapeutics (DCOY.US) — Financial Reports"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/DCOY.US/norm.md"
symbol: "DCOY.US"
name: "Decoy Therapeutics"
parent: "https://longbridge.com/en/quote/DCOY.US.md"
datetime: "2026-05-21T13:43:13.650Z"
locales:
  - [en](https://longbridge.com/en/quote/DCOY.US/norm.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/DCOY.US/norm.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/DCOY.US/norm.md)
---

# Decoy Therapeutics (DCOY.US) — Financial Reports

## Income Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| EPS | -4.18 | -23.46 | - | - | - |
| ROE | -182.23% | -708.50% | -204.42% | 997.92% | -869.13% |
| Revenue | - | - | - | - | - |
| Net income | -2.22M | -8.98M | -873467.00 | -957825.00 | -1.71M |
| Operating income | -2.28M | -516596.00 | -895130.00 | -965565.00 | -1.72M |
| Gross margin | - | - | - | - | - |
| Net margin | - | - | - | - | - |
| Profit quality | - | - | - | - | - |

## Balance Sheet (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| A&L | 8.42M | 11.06M | 6.10M | 1.39M | 2.34M |
| Leverage | 2.17 | 1.88 | 1.44 | -1.68 | 37.81 |
| BVPS | 7.29 | 11.07 | 53.97 | - | - |
| Turnover | - | - | - | - | - |
| Cash & STI | 7.82M | 10.71M | 4.81M | 794886.00 | 1.80M |
| Inv & Rec | - | - | - | - | - |
| LT assets | 35741.00 | 40559.00 | - | - | - |
| Net debt | -7.82M | -10.71M | -4.81M | -794886.00 | -1.69M |

## Cash Flow Statement (USD)

| Indicator | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
| --- | --- | --- | --- | --- | --- |
| Operating CF | -2.89M | -1.14M | -1.65M | -862297.00 | -1.18M |
| Investing CF | - | 964735.00 | -200000.00 | - | - |
| Financing CF | - | 6.07M | 5.86M | -141197.00 | 545566.00 |
| Free CF | -2.31M | 4.12M | -1.62M | -603152.00 | -117333.00 |
| OCF coverage | - | - | - | -768.33% | -1077.85% |
| Repaid & issued | - | - | - | - | - |
| CapEx | - | - | - | - | - |